Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

6 Jun 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center today announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia.

4 Jun 2011

U-M study shows decline in surgery mortality for eight different high-risk operations

Surgery death rates have dropped nationwide over the past decade, according to a University of Michigan Health System study that reveals cancer surgeries have seen the most dramatic improvement in safety.

3 Jun 2011

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Repligen Corporation today announced that the Company has concluded a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration related to its lead product candidate, RG1068 for improvement of magnetic resonance imaging of the pancreas.

2 Jun 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Davos Life Science has today announced preliminary results of a phase I clinical trial of its Natural e3 delta-tocotrienol (Natural e3) in patients with resectable pancreatic cancer. Tocotrienols are highly potent members of the Vitamin E family that have been found by researchers to inhibit the growth and survival of various types of cancer cells.

30 May 2011

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

ProteaBio Europe SAS, announced today that the company, in partnership with Mayoly-Spindler, has successfully completed a Phase I/IIA human clinical trial for their MS1819 recombinant Lipase.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

21 May 2011

Coffee reduces prostate cancer risk

In the 20-year study of almost 50,000 men, researchers noted that those who drank at least six cups a day were 20 per cent less likely to get prostate cancer than those who never took coffee. Strikingly, they were 60 per cent less likely than the non-coffee drinkers to die of the disease. The researchers also say that decaffeinated coffee is just as effective.

17 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

Swedish adds new virtual reality training simulator to help surgeons practice on robotic-assisted system

As one of the first medical centers in the Northwest to perform robotic-assisted surgery, Swedish is home to the fastest growing, most comprehensive and experienced robotic-assisted surgical program in the region. Swedish established the multidisciplinary, robotic-assisted surgical program in 2005 and has since performed more than 3,400 robotic-assisted surgeries -- more than any other program in the region.

12 May 2011

Noninvasive stool test can detect pancreatic cancer

Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason for this high number of deaths is a lack of effective screening tools for catching the disease early.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

Geron comments on recent European telomerase peptide cancer vaccine patents

Geron Corporation today commented on a ruling from the European Patent Office with regard to its European patent 084139, and the issuance of a second Geron patent covering telomerase peptides, EP1783139.

10 May 2011

Rapid blood-based test can determine patients with SLE

"At present, it can take up to a year before a patient is diagnosed with SLE. This is because the symptoms are diffuse and are often mistaken for other diseases. However, with this blood-based test, it is possible to determine quickly whether someone has the disease or not", says Christer Wingren, associate professor in Immunotechnology at CREATE Health, Lund University.

10 May 2011

Boston Scientific launches Expect Endoscopic Ultrasound Aspiration Needle

Boston Scientific Corporation today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adjacent to the gastrointestinal tract. The Expect Needle received FDA clearance and CE Mark approval earlier this year and is being marketed in the U.S., Europe and other international markets.

9 May 2011

KAEL-GemVax wins European telomerase patent challenge

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.

9 May 2011

Pancreatic Cancer News and Research

Further Reading

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

U-M study shows decline in surgery mortality for eight different high-risk operations

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Mayoly-Spindler, ProteaBio complete MS1819 Phase I/IIA trial in malabsorption syndrome

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

Coffee reduces prostate cancer risk

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Swedish adds new virtual reality training simulator to help surgeons practice on robotic-assisted system

Noninvasive stool test can detect pancreatic cancer

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Geron comments on recent European telomerase peptide cancer vaccine patents

Rapid blood-based test can determine patients with SLE

Boston Scientific launches Expect Endoscopic Ultrasound Aspiration Needle

KAEL-GemVax wins European telomerase patent challenge

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News